Phio Pharmaceuticals CORP Schedule 13G passive stakes

CVI Investments and Heights Capital Management have jointly reported a 9.9% beneficial ownership stake in Phio Pharmaceuticals Corp., primarily through warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 9.1% beneficial ownership stake in Phio Pharmaceuticals Corp. as of December 31, 2025.

Orca Capital AG has filed an Amendment No. 5 to Schedule 13G, reporting a 4.9% beneficial ownership stake in Phio Pharmaceuticals Corp. as of December 8, 2025.

Orca Capital AG has reported a 6.5% beneficial ownership stake in Phio Pharmaceuticals Corp., holding 700,421 shares of common stock.

Orca Capital AG has filed an amended Schedule 13G, reporting a 4.9% beneficial ownership stake in Phio Pharmaceuticals Corp. as of November 7, 2025.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a 9.9% beneficial ownership stake in Phio Pharmaceuticals Corp. common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 7.0% beneficial ownership in Phio Pharmaceuticals Corp. common stock.

Orca Capital AG has disclosed an increased beneficial ownership of 9.8% in Phio Pharmaceuticals Corp., holding 800,000 shares of common stock.

Orca Capital AG has filed an amended Schedule 13G, disclosing a 4.9% beneficial ownership stake in Phio Pharmaceuticals Corp.

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly disclosed a passive beneficial ownership of 4.9% in Phio Pharmaceuticals Corp., primarily through warrants, as of December 31, 2024.

Orca Capital AG discloses a 9.9% ownership stake in Phio Pharmaceuticals Corp. as of December 19, 2024.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 9.99% of Phio Pharmaceuticals Corp.'s common stock, totaling 530,171 shares as of January 17, 2025.